Shilpa Medicare Ltd Share Price – NSE  / BSE

Pharmaceuticals, Small Cap

The inspection was conducted from 24 September 2024 to 26 September 2024. On conclusion of the inspection the company has received the Good Manufacturing Practice (GMP) Certification.

Unit VII of Shilpa Medicare houses an Analytical Services Division (QC) and a Bio-Analytical Department, both of which are approved by the USFDA. Notably, the Bio-Analytical Laboratory is already approved by EMA, Europe.

This inspection was the first Europe inspection for the QC laboratory of Unit VII. This Laboratory is involved in testing drug substances, raw materials, packing materials and finished products. It is also engaged in other analytical activities like analytical method validations, method transfers and other miscellaneous analytical studies. The laboratory has been testing samples for final release into US, EU and other markets.

Raichur-based Shilpa Medicare is a vertically integrated manufacturer and distributor of quality drugs to global markets, specializing in the oncology therapeutic segment and introducing novel drugs focusing on patient convenience and compliance.

The company’s consolidated net profit soared to Rs 17.94 crore in Q2 FY25 as against Rs 1.61 crore posted in Q2 FY24. Revenue from operations rose 9.8% to Rs 343.80 crore in the quarter ended 30 September 2024.

The scrip shed 0.03% to Rs 828.75 on the BSE.

Powered by Capital Market - Live News

Oncosol is 50:50 joint venture between Liqmeds Lifecare, a Zydus Group company, and Koana Healthcare, a Shilpa Medicare Group company.

IMKELDI is an advanced liquid formulation of imatinib designed for dosing accuracy. It helps slow or prevent the growth of specific cancers, including chronic myeloid leukemia (CML), acute lymphoblastic leukemia, myelodysplastic syndrome (MDS), myeloproliferative disease (MPD), and gastrointestinal tumors (GIST).

“In 2024, an estimated 9,280 people will be diagnosed with CML, over 10,000 with MDS/MPD, and up to 6,000 with GIST in the U.S. Despite the proven clinical benefits of imatinib, patient adherence can be an issue, underscoring a critical unmet need for a more accessible, patient-friendly oral solution delivery system,” the company stated in exchange filing.

Raichur-based Shilpa Medicare is a vertically integrated manufacturer and distributor of quality drugs to global markets, specializing in the oncology therapeutic segment and introducing novel drugs focusing on patient convenience and compliance.

The company’s consolidated net profit soared to Rs 17.94 crore in Q2 FY25 as against Rs 1.61 crore posted in Q2 FY24. Revenue from operations rose 9.8% to Rs 343.80 crore in the quarter ended 30 September 2024.

The scrip rose 0.42% to Rs 892.50 on the BSE.

Powered by Capital Market - Live News

Albumin is in high demand for various medical treatments, including restoring blood volume and replacing lost fluids during accidents, serious burn injuries, fatal erythroblastosis, hypoproteinemia, and surgeries. However, the supply of human serum albumin is limited due to the reliance on whole blood or donated human plasma. Shilpa’s Recombinant Human Albumin 20% (rHA), derived from yeast, offers a highly purified, structurally and functionally equivalent alternative to human serum albumin.

The company has successfully completed its Phase I clinical trials on 7 August 2024. With today’s announcement, the company confirms that the SEC has accepted the trial results and approved the progression to Phase III trials for rHA 20%.

The Phase III trials will be conducted according to the protocol approved by the SEC.

Shilpa is the first company in India to receive the approval for conducting Phase III clinical trials. This approval clears regulatory strategy for India and various emerging markets that accept Indian studies and is an important step towards providing a reliable and safe alternative to human serum albumin, addressing the global demand and supply challenges.

Raichur-based Shilpa Medicare is a vertically integrated, manufacturer and distributor of quality drugs to global markets; specializing in the oncology therapeutic segment and introducing novel drugs focusing on patient convenience and compliance.

The company’s consolidated net profit soared to Rs 17.94 crore in Q2 FY25 as against Rs 1.61 crore posted in Q2 FY24. Revenue from operations rose 9.8% to Rs 343.80 crore in the quarter ended 30 September 2024.

The scrip shed 0.66% to Rs 889.25 on the BSE.

Powered by Capital Market - Live News

The key equity indices traded with substantial gains in early afternoon trade. The Nifty traded above the 23,700 level. Auto shares extended gains for the third consecutive trading session.

At 12:30 IST, the barometer index, the S&P BSE Sensex, climbed 1,007.70 points or 1.30% to 78,346.71. The Nifty 50 index soared 293.40 points or 1.25% to 23,747.20.

In the broader market, the S&P BSE Mid-Cap index rallied 1.72% and the S&P BSE Small-Cap index jumped 1.80%.

The market breadth was strong. On the BSE, 2,862 shares rose and 942 shares fell. A total of 120 shares were unchanged.

Derivatives:

The NSE's India VIX, a gauge of the market's expectation of volatility over the near term, tumbled 5.35% to 14.36. The Nifty 28 November 2024 futures were trading at 23,816.35, at a premium of 69.15 points as compared with the spot at 23,747.20.

The Nifty option chain for the 28 November 2024 expiry showed maximum Call OI of 42.01 lakh contracts at the 24,000 strike price. Maximum Put OI of 53.8 lakh contracts were seen at 23,000 strike price.

Buzzing Index:

The Nifty Auto index added 2.33% to 23,581.15. The index rallied 3.58% in the three consecutive trading sessions.

Mahindra & Mahindra (up 3.63%), Apollo Tyres (up 3.29%), Exide Industries (up 3.16%), Bharat Forge (up 3.05%) and Bosch (up 2.9%), Tata Motors (up 2.73%), Eicher Motors (up 2.55%), Hero MotoCorp (up 2.42%), Samvardhana Motherson International (up 2.17%) and TVS Motor Company (up 2.01%) advanced.

Stocks in Spotlight :

Shilpa Medicare rallied 3.77% after the company’s 100% subsidiary, Shilpa Pharma Lifesciences received certificate of suitability (CEP) from EDQM (European Directorate for the Quality of Medicines & Healthcare) for API, Octreotide.

Meanwhile, Shilpa Pharma Lifesciences also received certificate of suitability (CEP) from EDQM (European Directorate for the Quality of Medicines & Healthcare) for API, Nifedipine.

V-Mart Retail rose 0.85%. The company informed that a fire accident occurred at one of its stores located in Ahmedabad, Gujarat, on Monday, 18 November 2024.

Easy Trip Planners added 2.27% after the company’s board fixed Thursday, 8 November 2024 as the record date for the proposed bonus issue of equity shares. On 14 October 2024, the company’s board had approved the issuance of one bonus equity share for every one fully paid-up equity share held by shareholders (1:1) as on record date.

Powered by Capital Market - Live News